SOD2 and non-small cell lung carcinoma: During the process of getting FDA approval for a Phase I Clinical Trial of esophagus radiation protection in unresectable non-small cell lung cancer patients, FDA examiners requested a list of the potential complications of the administration of MnSOD-PL to normal tissues.